Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Sage TherapeuticsArena PharmaceuticalsHutchison China MediTechReata PharmaceuticalsPTC Therapeutics
SymbolNASDAQ:SAGENASDAQ:ARNANASDAQ:HCMNASDAQ:RETANASDAQ:PTCT
Price Information
Current Price$73.25$66.40$29.63$86.46$47.30
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.71.41.41.3
Analysis Score3.34.53.53.53.3
Community Score3.12.42.72.62.5
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.80.0
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$87.06$92.80$40.00$251.25$64.90
% Upside from Price Target18.86% upside39.76% upside35.00% upside190.60% upside37.21% upside
Trade Information
Market Cap$4.20 billion$4.01 billion$4.31 billion$3.13 billion$3.33 billion
Beta2.230.831.121.571.22
Average Volume498,601505,044239,001290,331547,068
Sales & Book Value
Annual Revenue$6.87 million$806.43 million$204.89 million$26.52 million$306.98 million
Price / Sales622.494.9721.05118.0210.84
CashflowN/A$6.51 per shareN/AN/AN/A
Price / CashN/A10.20N/AN/AN/A
Book Value$18.23 per share$21.38 per share$2.35 per share$7.74 per share$9.64 per share
Price / Book4.023.1112.6111.174.91
Profitability
Net Income$-680,240,000.00$397.55 million$-106,020,000.00$-290,170,000.00$-251,580,000.00
EPS($13.38)$7.69($0.80)($9.54)($3.45)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-7,706.84%N/AN/A-4,340.72%-123.19%
Return on Equity (ROE)-63.81%-33.17%N/A-163.42%-76.10%
Return on Assets (ROA)-56.64%-30.41%N/A-56.49%-24.60%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.04%0.07%N/A1.89%
Current Ratio11.71%23.17%3.14%12.98%4.90%
Quick Ratio11.71%23.17%3.01%12.98%4.83%
Ownership Information
Institutional Ownership PercentageN/A89.67%33.45%64.30%N/A
Insider Ownership Percentage4.80%3.05%N/A31.70%7.00%
Miscellaneous
Employees2983631,280261959
Shares Outstanding58.38 million60.34 million145.54 million36.20 million70.32 million
Next Earnings Date5/6/2021 (Estimated)5/6/2021 (Estimated)N/A5/10/2021 (Estimated)4/29/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
RBC Capital Stick to Their Hold Rating for PTC TherapeuticsRBC Capital Stick to Their Hold Rating for PTC Therapeutics
investing.com - April 12 at 1:38 PM
Zacks: Brokerages Expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to Announce -$1.59 Earnings Per ShareZacks: Brokerages Expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to Announce -$1.59 Earnings Per Share
americanbankingnews.com - April 10 at 4:16 PM
PTC Therapeutics Received Gallups "Don Clifton Strengths-Based Culture" AwardPTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award
finance.yahoo.com - April 7 at 12:58 PM
PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive WebinarPTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar
prnewswire.com - April 7 at 8:55 AM
PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™
finance.yahoo.com - April 1 at 8:55 AM
Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular AtrophyRoche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy
morningstar.com - March 30 at 10:37 AM
PTC Therapeutics-Roches Evrysdi Approved In Europe For Muscular AtrophyPTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy
finance.yahoo.com - March 30 at 10:37 AM
PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular AtrophyPTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy
finance.yahoo.com - March 30 at 1:07 AM
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Sector Perform by Royal Bank of CanadaPTC Therapeutics (NASDAQ:PTCT) Upgraded to Sector Perform by Royal Bank of Canada
americanbankingnews.com - March 29 at 11:12 AM
PTC Therapeutics (NASDAQ:PTCT) Raised to Sector Perform at Royal Bank of CanadaPTC Therapeutics (NASDAQ:PTCT) Raised to Sector Perform at Royal Bank of Canada
marketbeat.com - March 29 at 8:16 AM
Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA PatientsResults from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
finance.yahoo.com - March 24 at 1:30 AM
PTCT Makes Notable Cross Below Critical Moving AveragePTCT Makes Notable Cross Below Critical Moving Average
nasdaq.com - March 23 at 3:15 PM
PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 7.1%PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 7.1%
americanbankingnews.com - March 23 at 12:00 PM
Interesting PTCT Put And Call Options For May 21stInteresting PTCT Put And Call Options For May 21st
nasdaq.com - March 23 at 10:09 AM
PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Hold" at Zacks Investment ResearchPTC Therapeutics (NASDAQ:PTCT) Upgraded to "Hold" at Zacks Investment Research
marketbeat.com - March 17 at 3:50 AM
Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA PatientsResults from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
markets.businessinsider.com - March 16 at 2:13 AM
PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with DystrophinopathiesPTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies
finance.yahoo.com - March 15 at 12:58 PM
Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative MedicineSpinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine
finance.yahoo.com - March 9 at 9:15 AM
CHMP Adopts Positive Opinion for Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and OlderCHMP Adopts Positive Opinion for Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older
stockhouse.com - February 26 at 10:15 AM
CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and OlderCHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older
finance.yahoo.com - February 26 at 10:15 AM
PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate UpdatePTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
markets.businessinsider.com - February 25 at 6:45 PM
PTC Therapeutics, Inc. to Host Earnings CallPTC Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - February 25 at 6:45 PM
Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of MedicinePositive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine
finance.yahoo.com - February 24 at 5:43 PM
PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19
finance.yahoo.com - February 17 at 9:28 AM
Loss-Making PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected To Breakeven In The Medium-TermLoss-Making PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected To Breakeven In The Medium-Term
finance.yahoo.com - February 15 at 10:20 AM
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial ResultsPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
finance.yahoo.com - February 11 at 8:24 AM
PTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular DystrophyPTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
finance.yahoo.com - February 4 at 7:41 PM
DateCompanyBrokerageAction
4/12/2021Sage TherapeuticsMizuhoReiterated Rating
4/7/2021Sage TherapeuticsPiper SandlerInitiated Coverage
3/8/2021Sage TherapeuticsMorgan StanleyBoost Price Target
3/3/2021Sage TherapeuticsOppenheimerBoost Price Target
2/25/2021Sage TherapeuticsHC WainwrightBoost Price Target
2/1/2021Sage TherapeuticsRaymond JamesInitiated Coverage
1/22/2021Sage TherapeuticsBMO Capital MarketsDowngrade
1/19/2021Sage TherapeuticsWedbushBoost Price Target
1/4/2021Sage TherapeuticsGuggenheimUpgrade
1/4/2021Sage TherapeuticsRoyal Bank of CanadaDowngrade
12/4/2020Sage TherapeuticsWilliam BlairReiterated Rating
12/1/2020Sage TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
12/1/2020Sage TherapeuticsTruistBoost Price Target
12/1/2020Sage TherapeuticsSmith Barney CitigroupLower Price Target
4/13/2021Arena PharmaceuticalsCredit Suisse GroupBoost Price Target
3/9/2021Arena PharmaceuticalsCantor FitzgeraldLower Price Target
3/3/2021Arena PharmaceuticalsSVB LeerinkLower Price Target
3/3/2021Arena PharmaceuticalsJonestradingLower Price Target
11/2/2020Arena PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
9/30/2020Arena PharmaceuticalsBank of AmericaBoost Price Target
8/6/2020Arena PharmaceuticalsWells Fargo & CompanyBoost Price Target
8/6/2020Arena PharmaceuticalsNeedham & Company LLCReiterated Rating
10/2/2020Hutchison China MediTechDeutsche Bank AktiengesellschaftInitiated Coverage
2/20/2020Hutchison China MediTechThe Goldman Sachs GroupInitiated Coverage
11/19/2019Hutchison China MediTechCLSAInitiated Coverage
7/5/2019Hutchison China MediTechMacquarieInitiated Coverage
3/27/2019Hutchison China MediTechHSBCInitiated Coverage
8/10/2020Reata PharmaceuticalsStifel NicolausLower Price Target
6/16/2020Reata PharmaceuticalsBTIG ResearchInitiated Coverage
6/12/2020Reata PharmaceuticalsRobert W. BairdReiterated Rating
4/17/2020Reata PharmaceuticalsJefferies Financial GroupBoost Price Target
11/13/2019Reata PharmaceuticalsNational SecuritiesDowngrade
10/28/2020PTC TherapeuticsUBS GroupInitiated Coverage
7/20/2020PTC TherapeuticsCowenReiterated Rating
7/20/2020PTC TherapeuticsSunTrust BanksBoost Price Target
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.